mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease

被引:37
|
作者
Belibi, Franck
Ravichandran, Kameswaran
Zafar, Iram
He, Zhibin
Edelstein, Charles L. [1 ]
机构
[1] Univ Colorado Denver, Div Renal Dis & Hypertens, Aurora, CO 80262 USA
基金
美国国家卫生研究院;
关键词
cyst volume; kidney size; autosomal dominant polycystic kidney disease; AUTOSOMAL-DOMINANT; CELL-PROLIFERATION; TRANSGENIC MICE; CYST FORMATION; C-MYC; PROGRESSION; ACTIVATION; APOPTOSIS; PATHWAY; KINASE;
D O I
10.1152/ajprenal.00129.2010
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Belibi F, Ravichandran K, Zafar I, He Z, Edelstein CL. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am J Physiol Renal Physiol 300: F236-F244, 2011. First published October 13, 2010; doi: 10.1152/ajprenal.00129.2010.-Rapamycin slows disease progression in the male Han: SPRD (Cy/+) rat with polycystic kidney disease (PKD). The aim of this study was to determine the effect of rapamycin on PKD and the relative contributions of the proproliferative mammalian target of rapamycin complexes 1 and 2 (mTORC1 and mTORC2) in female Cy/+ rats. Female Cy/+ rats were treated with rapamycin from 4 to 12 wk of age. In vehicle-treated Cy/+ rats, kidney volume increased by 40% and cyst volume density (CVD) was 19%. Phosphorylated S6 (p-S6) ribosomal protein, a marker of mTORC1 activity, was increased in Cy/+ rats compared with normal littermate controls (+/+) and decreased by rapamycin. Despite activation of mTORC1 in female Cy/+ rats, rapamycin had no effect on kidney size, CVD, number of PCNA-positive cystic tubular cells, caspase-3 activity, or the number of terminal deoxynucleotidyl transferase dUTP-mediated nick-end label-positive apoptotic cells. To determine a reason for the lack of effect of rapamycin, we studied the mTORC2 signaling pathway. On immunoblot of kidney, phosphorylated (Ser(473)) Akt (p-Akt), a marker of mTORC2 activity, was increased in female Cy/+ rats treated with rapamycin. Phosphorylated (Ser(657)) PKC alpha, a substrate of mTORC2, was unaffected by rapamycin in females. In contrast, in male rats, where rapamycin significantly decreases PKD, p-Akt (Ser(473)) was decreased by rapamcyin. PKC alpha (Ser(657)) was increased in male Cy/+ rats but was unaffected by rapamycin. In summary, in female Cy/+ rats, rapamycin had no effect on PKD and proproliferative p-Akt (Ser(473)) activity was increased by rapamycin. There were differential effects of rapamycin on mTORC2 signaling in female vs. male Cy/+ rats.
引用
收藏
页码:F236 / F244
页数:9
相关论文
共 50 条
  • [1] Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease
    Zhang, Tong
    Wang, Li
    Xiong, Xishan
    Mao, Zhiguo
    Wang, Liming
    Mei, Changlin
    BIOLOGICAL RESEARCH, 2009, 42 (04) : 437 - 444
  • [2] Aggravation of polycystic kidney disease in Han:SPRD rats by buthionine sulfoximine
    Torres, VE
    Bengal, RJ
    Litwiller, RD
    Wilson, DM
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 (08): : 1283 - 1291
  • [3] Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action
    Liu, Chunyan
    Li, Hongdong
    Gao, Xiang
    Yang, Ming
    Yuan, Li
    Fu, Lili
    Wang, Xueqi
    Mei, Changlin
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2018, 314 (05) : F844 - F854
  • [4] A Sphingosine-1-Phosphate Modulator Ameliorates Polycystic Kidney Disease in Han:SPRD Rats
    Li, Xin
    Wu, Ming
    Chen, Limin
    Lu, Junyan
    Li, Guo
    Fu, Lili
    Qi, Na
    Lin, Ye
    Sun, Zhongya
    Wang, Xueqi
    Zhang, Hao
    Liu, Jingqiu
    Jiang, Hualiang
    Li, Lin
    Mei, Chang-Lin
    Luo, Cheng
    AMERICAN JOURNAL OF NEPHROLOGY, 2020, 51 (01) : 1 - 10
  • [5] Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats
    Dai, Bing
    Liu, Yawei
    Mei, Changlin
    Fu, Lili
    Xiong, Xishan
    Zhang, Yan
    Shen, Xuefei
    Hua, Zhenhao
    CLINICAL SCIENCE, 2010, 119 (7-8) : 323 - 333
  • [6] The Han:SPRD Rat: A Preclinical Model of Polycystic Kidney Disease
    Kofotolios, Ioannis
    Bonios, Michael J.
    Adamopoulos, Markos
    Mourouzis, Iordanis
    Filippatos, Gerasimos
    Boletis, John N.
    Marinaki, Smaragdi
    Mavroidis, Manolis
    BIOMEDICINES, 2024, 12 (02)
  • [7] Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)
    Zafar, Iram
    Belibi, Franck A.
    He, Zhibin
    Edelstein, Charles L.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (08) : 2349 - 2353
  • [8] The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats
    Kanno, Y
    Okada, H
    Moriwaki, K
    Nagao, S
    Takahashi, H
    Suzuki, H
    HYPERTENSION RESEARCH, 2002, 25 (06) : 939 - 943
  • [9] Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease
    Wahl, Patricia R.
    Le Hir, Michel
    Vogetseder, Alexander
    Arcaro, Alexandre
    Starke, Astrid
    Waeckerle-Men, Ying
    Serra, Andreas L.
    Wuthrich, Rudolf P.
    NEPHROLOGY, 2007, 12 (04) : 357 - 363
  • [10] Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
    Rodriguez, Daniel
    Kapoor, Sarika
    Edenhofer, Ilka
    Segerer, Stephan
    Riwanto, Meliana
    Kipar, Anja
    Yang, Ming
    Mei, Changlin
    Wuethrich, Rudolf P.
    KIDNEY & BLOOD PRESSURE RESEARCH, 2015, 40 (06): : 638 - 647